Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBT Margin: 2016-2025

Historic EBT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to 1.97%.

  • Akebia Therapeutics' EBT Margin rose 5551.00% to 1.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -6.79%, marking a year-over-year decrease of 31873.00%. This contributed to the annual value of -43.33% for FY2024, which is 47592.00% up from last year.
  • As of Q3 2025, Akebia Therapeutics' EBT Margin stood at 1.97%, which was up 397.10% from 0.40% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' EBT Margin ranged from a high of 22.98% in Q2 2022 and a low of -159.32% during Q2 2021.
  • Its 3-year average for EBT Margin is -26.03%, with a median of -19.82% in 2023.
  • Within the past 5 years, the most significant YoY rise in Akebia Therapeutics' EBT Margin was 27,672bps (2021), while the steepest drop was 6,468bps (2021).
  • Quarterly analysis of 5 years shows Akebia Therapeutics' EBT Margin stood at -122.10% in 2021, then skyrocketed by 11,044bps to -11.66% in 2022, then skyrocketed by 1,118bps to -0.48% in 2023, then tumbled by 4,857bps to -49.04% in 2024, then surged by 5,551bps to 1.97% in 2025.
  • Its last three reported values are 1.97% in Q3 2025, 0.40% for Q2 2025, and 10.66% during Q1 2025.